PROF Stock Overview
Operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Profound Medical Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$4.78 |
| 52 Week High | CA$11.42 |
| 52 Week Low | CA$3.90 |
| Beta | 0.62 |
| 1 Month Change | -29.29% |
| 3 Month Change | -34.97% |
| 1 Year Change | -39.03% |
| 3 Year Change | -40.32% |
| 5 Year Change | -61.20% |
| Change since IPO | -53.07% |
Recent News & Updates
Shareholder Returns
| PROF | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 6.6% | -2.8% | -3.0% |
| 1Y | -39.0% | 3.2% | 4.6% |
Return vs Industry: PROF underperformed the US Medical Equipment industry which returned 3.2% over the past year.
Return vs Market: PROF underperformed the US Market which returned 4.6% over the past year.
Price Volatility
| PROF volatility | |
|---|---|
| PROF Average Weekly Movement | 6.6% |
| Medical Equipment Industry Average Movement | 9.0% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 4.0% |
Stable Share Price: PROF has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PROF's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 142 | Arun Menawat | www.profoundmedical.com |
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. The company’s lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors.
Profound Medical Corp. Fundamentals Summary
| PROF fundamental statistics | |
|---|---|
| Market cap | US$144.38m |
| Earnings (TTM) | -US$27.82m |
| Revenue (TTM) | US$10.68m |
13.4x
P/S Ratio-5.2x
P/E RatioIs PROF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PROF income statement (TTM) | |
|---|---|
| Revenue | US$10.68m |
| Cost of Revenue | US$3.64m |
| Gross Profit | US$7.04m |
| Other Expenses | US$34.85m |
| Earnings | -US$27.82m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 08, 2025
| Earnings per share (EPS) | -0.93 |
| Gross Margin | 65.89% |
| Net Profit Margin | -260.45% |
| Debt/Equity Ratio | 7.7% |
How did PROF perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/17 21:44 |
| End of Day Share Price | 2025/04/17 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Profound Medical Corp. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Kideckel | Beacon Securities Limited |
| Jason Mills | Canaccord Genuity |
| Prakash Gowd | CIBC Capital Markets |